Ensign Peak Advisors’s Heron Therapeutics HRTX Stock Holding History

Ensign Peak Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-175,572	Closed	-$740K	–	1973
2022 Q3	$740K	Buy	175,572 +161,531	+1,150%	+$632K	﹤0.01%	1246
2022 Q2	$39K	Sell	14,041 -21,539	-61%	-$86.5K	﹤0.01%	2089
2022 Q1	$204K	Sell	35,580 -117,275	-77%	-$858K	﹤0.01%	1873
2021 Q4	$1.4M	Buy	152,855 +29,740	+24%	+$304K	﹤0.01%	1112
2021 Q3	$1.32M	Buy	+123,115	New	+$1.5M	﹤0.01%	1319
2020 Q3	–	Sell	-4,869	Closed	-$72K	–	1752
2020 Q2	$72K	Hold	4,869	–	–	﹤0.01%	1649
2020 Q1	$57K	Sell	4,869 -5,870	-55%	-$110K	﹤0.01%	1600
2019 Q4	$253K	Buy	+10,739	New	+$238K	﹤0.01%	1608

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Ensign Peak Advisors's HRTX Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 175,572 shares — an estimated $740K sold.

Ensign Peak Advisors first reported a position in HRTX in Q4 2019 and held it in 8 quarters. The position peaked at $1.4M in Q4 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Ensign Peak Advisors reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Ensign Peak Advisors sold 175,572 Heron Therapeutics shares in Q4 2022, an estimated $740K.
Ensign Peak Advisors first reported a position in Heron Therapeutics in Q4 2019 and held it in 8 quarters.
Ensign Peak Advisors's Heron Therapeutics position peaked at $1.4M in Q4 2021.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.